Study #2019-0930
The Comparison of Intravesical Therapy and Surgery as Treatment Options (CISTO) for Bladder Cancer Study
MD Anderson Study Status
Enrolling
Treatment Agent
Description
Bladder cancer is the most common urinary tract cancer and the 5th most common cancer in the US (1). Yet bladder cancer research is underfunded relative to other common cancers. As a result, bladder cancer care is prone to evidence gaps that produce decision uncertainty for both patients and clinicians. The Comparison of Intravesical Therapy and Surgery as Treatment Options (CISTO) for Bladder Cancer Study has the potential to fill these critical evidence gaps, change care pathways for the management of NMIBC (non-muscle-invasive bladder cancer), and provide for personalized, patient-centered care. The purpose of CISTO is to conduct a large prospective study that directly compares the impact of medical management versus bladder removal in recurrent high-grade NMIBC patients with BCG (Bacillus Calmette-Guerin) failure on clinical outcomes and patient and caregiver experience using standardized patient-reported outcomes (PROs).
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Bladder Cancer;Cancer of the Bladder, Recurrent;Non-muscle Invasive Bladder Cancer
Study phase:
Physician name:
Ashish Kamat
Department:
Urology
For general questions about clinical trials:
1-855-982-0789
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.